Key Highlights
- Kooth PLC (LSE:KOO), the AIM-quoted digital mental health provider, is shrinking at the Top Line while becoming markedly more profitable underneath.
- Its half-year trading update on 29 July 2026 guided to adjusted EBITDA of £5.0m to £5.4m for the six months to 30 June 2026, more than three times the £1.6m reported a year earlier, on Revenue that slipped 4% to £30.8m.
- Kooth's 29 July 2026 update covered the six months to 30 June 2026.
- Revenue of £30.8m compared with £32.1m a year earlier.
Kooth PLC (LSE: KOO), the AIM-quoted digital mental health provider, is shrinking at the top line while becoming markedly more profitable underneath. Its half-year trading update on 29 July 2026 guided to adjusted EBITDA of £5.0m to £5.4m for the six months to 30 June 2026, more than three times the £1.6m reported a year earlier, on revenue that slipped 4% to £30.8m. Net cash rose to £23.1m. The question for a market that values the company at roughly £65m, according to Sharecast data on 2 September 2026, is whether that Margin recovery can be paired with renewed growth. The answers will come from interim results due in September, the trajectory of its flagship California contract, and whether the "State Alliance Model" can add more US states after Michigan.
Half-year trading update: profit recovers, revenue still soft
Kooth's 29 July 2026 update covered the six months to 30 June 2026. Revenue of £30.8m compared with £32.1m a year earlier. Management attributed the decline to the planned tapering of product development work under the California contract and a £0.7m negative currency effect, partly offset by new Michigan revenue. The profit picture was far stronger. Adjusted EBITDA is expected to land between £5.0m and £5.4m, against £1.6m in the comparable period, when the company front-loaded £7.2m of user-acquisition Marketing in California. Net cash of £23.1m at 30 June 2026 compares with £15.3m a year earlier and £21.6m at 31 December 2025; the company has no debt. The update said Soluna, Kooth's California platform, had reached 187,000 registrations by the end of June 2026, exceeding performance targets in what the company described as the fourth year of the contract. Chief executive Kate Newhouse said Kooth had "continued to build on the strong foundations we established in 2025." Full half-year results are scheduled for September 2026.
What Kooth does
Kooth provides digital mental health and wellbeing services commissioned by public-sector bodies rather than sold to consumers. Its platforms combine anonymous self-directed content, moderated peer communities and access to professional counsellors, delivered online. In the UK, Kooth is commissioned mainly by NHS integrated care boards and local authorities, and says it is the largest single access provider for under-18s mental health support in England, citing NHS data for 2024/25. The US is now the larger business. The 2024 launch of Soluna across all 58 California counties for the state's Department of Health Care Services (DHCS) transformed the company's scale. A New Jersey contract was renewed in October 2025, the group's first US renewal, and a one-year $2.6m contract with Michigan was signed in January 2026 to serve up to 100,000 students aged 13 to 18. In November 2025 Kooth bought the intellectual property and four staff of Kismet Health, a US paediatric teletherapy platform for children aged five to 12, for an undisclosed, immaterial sum. In FY2025 the US contributed £46.1m of revenue and the UK £17.2m. Some 99% of revenue is recurring, with roughly three-quarters of revenue and half of expenses denominated in US dollars.
FY2025 results: a step back after a bumper 2024
Full-year results published on 8 April 2026 for the year to 31 December 2025 showed revenue of £63.3m, down 5.2% from £66.7m in FY2024, or 2.7% lower at constant currency. Annual Recurring Revenue ended the year at £60.6m, compared with £66.4m a year earlier. Adjusted EBITDA fell 28.4% to £11.3m from £15.8m, operating profit dropped to £3.4m from £9.2m, and profit before tax was £4.4m against £9.9m. Net profit of £2.6m compared with £8.0m, with Basic Earnings Per Share of 7p versus 22p. Gross margin narrowed to 73.1% from 77.9%. Free Cash Flow shrank to £1.2m from £10.2m, although year-end cash was steady at £21.6m and the company retains an undrawn $9.5m working-capital facility. Constant-currency net revenue retention was 96% (FY2024: 100%). UK churn fell to £1.4m from £2.0m, but 14 new contracts did not offset pilot consolidations and funding constraints. Chair Peter Whiting called the revenue decline "nonetheless disappointing given Kooth's momentum." No Dividend was recommended. Guidance for 2026 was for revenue and adjusted EBITDA in line with market expectations, and the going-concern assessment runs to May 2027 with adequate headroom under downside scenarios.
What could move the shares next
The nearest catalyst is the audited interim results in September 2026, which will confirm the EBITDA range and give investors a fuller view of cash conversion and any update to full-year guidance. Beyond that, the US pipeline is the key swing factor. Kooth describes a "strong pipeline with diverse, bipartisan state partners" and says the Michigan contract could extend through additional funding. Independent validation from the DHCS 2025 Impact Report and Northwestern University research strengthens the sales case to other states, and the May 2026 appointment of James Polo, a former chief medical officer at United Healthcare of Washington, adds payer and Medicaid expertise to the board. In the UK, management expects to launch Soluna in the second half of 2026, and recent government recommendations favouring preventative support for young people could help commissioning. The Kismet Acquisition opens the under-12 market, while a formalised AI strategy could improve unit Economics over time.
Risks investors should watch
Customer concentration is the dominant risk. California generates the majority of group revenue, and Kooth's July update placed the contract in its fourth year; the company has not disclosed the renewal timetable in recent announcements, so any change in scope, funding or terms would be material. State budgets shift with political cycles, and the Michigan contract is only one year long. Revenue has declined for two consecutive reporting periods, and ARR at the end of 2025 was below the prior year. Currency is a further drag: with three-quarters of revenue in dollars but only half of costs, sterling strength cost £0.7m of revenue in the first half of 2026 alone. The UK Business faces NHS funding constraints and pilot consolidation, and the effective tax rate jumped to 40.3% in FY2025. With an AIM Market Value of around £65m, Liquidity can be thin.
Outlook
Kooth enters the second half of 2026 with a stronger balance sheet, a profit run-rate well ahead of last year and independent endorsements that few digital health peers can match. What it lacks is visible top-line growth. The September interim results should clarify whether the first-half EBITDA improvement is sustainable and whether 2026 guidance holds after the currency headwind. The larger prize is turning California's validation into additional state contracts before the current agreement approaches renewal. Investors will want evidence of new US wins, progress on the Soluna UK launch and stabilisation of UK churn. Until then, Kooth's next chapter depends heavily on decisions taken in Sacramento and other state capitals.






Please wait processing your request...